Cancer Therapies Access Debate

Full Debate: Read Full Debate

Lord Allan of Hallam

Main Page: Lord Allan of Hallam (Non-affiliated - Life peer)

Cancer Therapies Access

Lord Allan of Hallam Excerpts
Monday 6th February 2023

(1 year, 9 months ago)

Lords Chamber
Read Full debate Read Hansard Text Watch Debate
Lord Evans of Rainow Portrait Lord Evans of Rainow (Con)
- View Speech - Hansard - - - Excerpts

My Lords, I pay tribute to the noble Lord and the work that he has done on the All-Party Parliamentary Group on Minimally Invasive Cancer Therapies. In 2022-23, Health Education England is continuing to take forward priorities identified in the cancer workforce plan phase 1 and is investing an additional £50 million in 2022-23 to further expand the cancer and diagnosis workforce. Spending plans for individual budgets in 2023-24 to 2024-25 inclusive are subject to a detailed financial planning exercise and will be finalised in due course.

Lord Allan of Hallam Portrait Lord Allan of Hallam (LD)
- View Speech - Hansard - -

My Lords, as the noble Lord, Lord Aberdare, has already pointed out, interventional radiologists are essential to being able to provide minimally invasive cancer therapies. What is the Minister’s response to the Royal College of Radiologists’ 2021 census report, which painted a picture of growing concerns about the availability of interventional radiologists, as supply is not keeping up with demand? Will this particular shortage also be covered in the workforce plan? We will keep going on about the plan until we see it.

Lord Evans of Rainow Portrait Lord Evans of Rainow (Con)
- View Speech - Hansard - - - Excerpts

My Lords, NHS England commissions selective internal radiation therapy as a treatment of choice for patients with unresectable advanced hepatocellular carcinoma in accordance with technology appraisals and metastatic colorectal cancer in accordance with the NHS England clinical commissioning policy. It should be noted that the market engagement and prior information notice process permitted any NHS trust that hosts a specialist liver service and multidisciplinary team to put themselves forward, either independently or in partnership with other NHS trusts.